Glucose-dependent insulinotropic polypeptide (GIP)
Gastric inhibitory polypeptide, more commonly referred to as glucose-dependent insulinotropic polypeptide (GIP), is a gut-derived peptide hormone and protein target involved in the regulation of glucose metabolism.
Gastric inhibitory polypeptide, more commonly referred to as glucose-dependent insulinotropic polypeptide (GIP), is a gut-derived peptide hormone and protein target involved in the regulation of glucose metabolism. It is one of the principal incretin hormones released from the intestine in response to nutrient intake, and it contributes to the postprandial insulin response through glucose-dependent stimulation of pancreatic insulin secretion. Because of this physiology, GIP has long been of interest in metabolic disease research, particularly in type 2 diabetes and obesity.
In contemporary biomedical research, GIP is also important as a pharmacologic target. It is being incorporated into multi-agonist strategies alongside glucagon-like peptide-1 (GLP-1) and glucagon signaling to improve metabolic outcomes. This has made GIP relevant not only to endocrine physiology but also to the development of newer anti-obesity and antidiabetic therapies, including tirzepatide and retatrutide.
Where the papers sit
9 papers from the last 6 months study Glucose-dependent insulinotropic polypeptide (GIP) directly · updated from PubMed 11 Oct 2026
Study type 3 clinical trials · 1 observational · 3 human data · 2 unclassified
Themes one subject
Those 9 are all about one subject.
-
Gut Hormone Metabolic Therapies
Gut-hormone therapies are expanding from single GIP or GLP-1 agonism toward multi-receptor drugs such as tirzepatide and metabolically stable triple agonists. Studies address weight regain after bariatric surgery, type 2 diabetes, kidney outcomes, and cardiovascular and pancreatic hormone responses. GIP infusion remains physiologically heterogeneous, with effects on insulin and glucagon varying by hyperglycaemic context and combination with semaglutide. Nausea and uncertain product quality remain practical safety concerns as these treatments move into broader use.
Papers
The 9 papers from the last 6 months that study Glucose-dependent insulinotropic polypeptide (GIP) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Gut Hormone Metabolic Therapies (9)
- Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ case reports · 7 Oct 2026 PMID 42843917
- Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions. European journal of endocrinology · 19 Sept 2026 PMID 42762476
- Overview of weight loss medicines and practical advice for patients. Nursing standard (Royal College of Nursing (Great Britain) : 1987) · 1 Sept 2026 PMID 42676263
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. Journal of computer-aided molecular design · 30 Jul 2026 PMID 42530676
- Effects of Pharmacological GIP Infusion on Insulin, Glucagon, and Cardiovascular Responses During Hyperglycemia in Type 2 Diabetes. Diabetes · 14 Jul 2026 PMID 42447284
- The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. Bioscience reports · 17 Jun 2026 PMID 42307179
- Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity surgery · 5 Jun 2026 PMID 42247124
- Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology · 22 May 2026 PMID 42173109
- A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. The lancet. Diabetes & endocrinology · 11 May 2026 PMID 42114520
By study type
Clinical trials (3)
- Effects of Pharmacological GIP Infusion on Insulin, Glucagon, and Cardiovascular Responses During Hyperglycemia in Type 2 Diabetes. Diabetes · 14 Jul 2026 PMID 42447284
- Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology · 22 May 2026 PMID 42173109
- A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. The lancet. Diabetes & endocrinology · 11 May 2026 PMID 42114520
Observational studies and case reports (1)
- Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ case reports · 7 Oct 2026 PMID 42843917
Human data, design not indexed (3)
- Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions. European journal of endocrinology · 19 Sept 2026 PMID 42762476
- Overview of weight loss medicines and practical advice for patients. Nursing standard (Royal College of Nursing (Great Britain) : 1987) · 1 Sept 2026 PMID 42676263
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. Journal of computer-aided molecular design · 30 Jul 2026 PMID 42530676
Unclassified: not yet indexed with MeSH (2)
- The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. Bioscience reports · 17 Jun 2026 PMID 42307179
- Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity surgery · 5 Jun 2026 PMID 42247124
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-08-01 by Claude. Drafted by language models from published abstracts; not medical advice.